IV Iron Infusion Therapy Note

Date of Service: [Date of service]

Infusion Start Time: [Start time]

Infusion Stop Time: [Stop time]

Location: [Facility/unit/chair]

Provider: [Provider name and credentials]

Visit Type: [first exposure / subsequent dose]; [Dose number] of [total planned doses] (Include dose numbering if multi-dose course.)

Product Administered: [Brand name (generic name), concentration]

Indication and Clinical Background

Primary indication: [iron deficiency anemia / iron deficiency without anemia / functional iron deficiency]

Clinical goal: [replete iron stores / improve hemoglobin / pre-operative optimization / avoid transfusion / support ESA therapy]

Baseline labs: Hemoglobin [value, date]; Ferritin [value, date]; Transferrin saturation [value, date]

Suspected etiology: [Etiology or "under evaluation with plan"]

Oral iron history: [Formulation tried, tolerance, adherence, response, and reason IV iron is appropriate] (If oral iron history unavailable, document why and rationale for proceeding.)

Prior IV iron exposure: [Product, timing, efficacy, any reactions] (State "none" or "unknown" if applicable.)

Pre-Infusion Assessment

Contraindication checkpoint: (Use Yes/No/Not assessed; explain any Yes or Not assessed responses.)

• Known hypersensitivity to intended product: [Yes / No / Not assessed] [Explanation if needed]
• Iron overload concern: [Yes / No / Not assessed] [Explanation if needed]
• Active infection or febrile illness: [Yes / No / Not assessed] [Explanation if needed]
• Pregnancy status: [Not applicable / Negative / Positive / Unknown] [Explanation if needed]

Hypersensitivity risk factors: Prior IV iron reaction [Yes / No / Unknown]; Multiple drug allergies [Yes / No / Unknown]; Severe atopy [Yes / No / Unknown] (Include details if any are Yes.)

Baseline vitals: [BP, HR, RR, Temp, SpO2, Weight]

IV access: [Access type, site, gauge, patency]

Consent: [Obtained and documented in this note / Obtained and documented elsewhere / Not obtained]

Premedication: [None / Medication, dose, route, timing, and rationale]

Dose Determination and Administration

Dosing rationale: [Deficit calculation: weight, current Hb, target Hb, calculated deficit, planned total elemental iron] OR [Protocol-based: regimen name, indication alignment, rationale for dose]

Product selection rationale: [Product name and brief rationale for choice]

Administration:

• IV access used: [Type, site]
• Dose delivered: [Elemental iron mg, dilution/volume, infusion rate or duration]
• Completion: [Completed as planned / Not completed: reason]
• Monitoring: [Vitals stable per protocol / Abnormalities: specify findings and timing]

Infusion reaction: (Include only if reaction occurred; otherwise omit this paragraph.)

• Onset: [Time relative to infusion start or completion]
• Signs/symptoms: [Description with severity]
• Objective findings: [Vital sign changes, physical exam findings]
• Actions taken: [Infusion stopped/paused, medications given, escalation]
• Outcome: [Resolved / Improved / Persistent; patient disposition]
• Future precautions: [Product avoidance or rechallenge plan, premedication plan, allergy list updated: Yes / No]

Disposition and Follow-Up

Condition at end of observation: [Stable / At baseline / Other]

IV site after removal: [Intact, no erythema or tenderness / Other findings]

Discharge instructions: [Return precautions for delayed reactions and when to seek care]

Ordering clinician notified: [Yes / No] [Method]

Follow-up plan:

• CBC recheck: [Date or timeframe, typically 4–8 weeks] (State "not yet determined" if applicable.)
• Iron studies recheck: [Date or timeframe, typically 8–12 weeks after course completion] (Avoid early post-infusion ferritin.)
• Product-specific monitoring: [Not indicated / Specify monitoring and timeframe] (e.g., phosphate for ferric carboxymaltose in at-risk patients.)
• Etiology follow-up: [Planned evaluations and responsible clinician]
• Next infusion: [Scheduled date / To be scheduled] [Dose number of total] (Include if multi-dose series.)